Reply to: “Liver fibrosis and adverse outcomes in COVID-19”

por Ruiz-Margáin, Astrid, Campos-Murguía, Alejandro, González-Regueiro, José Alberto, Román-Calleja, Berenice Monserrat, Delint, Deyanira Kúsulas, Macías-Rodríguez, Ricardo Ulises
Publicado 2021

Liver fibrosis in patients with metabolic associated fatty liver disease is a risk factor for adverse outcomes in COVID-19

por Campos-Murguía, Alejandro, Román-Calleja, Berenice Monserrat, Toledo-Coronado, Israel Vicente, González-Regueiro, José Alberto, Solís-Ortega, Alberto Adrián, Kúsulas-Delint, Deyanira, Cruz-Contreras, Mariana, Cruz-Yedra, Nabila, Cubero, Francisco Javier, Nevzorova, Yulia Alexandrowna, Martínez-Cabrera, Carlos Fernando, Moreno-Guillén, Paulina, Lozano-Cruz, Oscar Arturo, Chapa-Ibargüengoitia, Mónica, Gulías-Herrero, Alfonso, Aguilar-Salinas, Carlos Alberto, Ruiz-Margáin, Astrid, Macías-Rodríguez, Ricardo Ulises
Publicado 2021